Colorectal Cancer Clinical Trial
Official title:
Increasing Colorectal Cancer Screening in a Safety-net Health System With a Focus on the Uninsured: Benefits and Costs.
Colon cancer (CRC) is a leading cause of cancer death in the United States. Screening can
prevent CRC death, but screening rates are suboptimal, especially for vulnerable populations
such as those with limited or no health insurance. This striking public health challenge
demands urgent implementation of evidence-based strategies to reduce avoidable CRC death.
Prior research has shown that a direct-to-consumer strategy of inviting patients by mail to
complete CRC screening may result in increased rates of screening completion. However, this
approach has not been tested extensively in vulnerable populations, such as the
under/uninsured, and minority populations often cared for by safety-net health systems.
Further, it is unclear whether patients are more likely to participate in one CRC screening
test versus another. Knowing this is important to designing programs for increasing
screening. For example, the planning and resources required for a screening program with
colonoscopy--which is a sensitive but invasive and expensive test--are very different from a
program with that uses stool testing to detect microscopic blood such as an immunochemical
stool blood test--which is a less sensitive, but non-invasive and cheap test.
Also, it is possible designing a program with a less sensitive, but more acceptable test
could prevent more CRC death if participation in screening is test specific. For example, if
many more patients participate in an immunochemical stool blood test based program than a
colonoscopy based program, even though the immunochemical stool blood test is less
sensitive, the program may save more lives because more patients are reached.
The aims of this trial are to:
Aim 1. Deliver CRC screening services (mailed invitation to screening, telephone reminders,
and systematic clinical follow up) to uninsured, unscreened patients cared for by the
safety-net health system serving Tarrant County, Texas. Patients will be invited to either:
1. Complete a free home-based, non-invasive immunochemical stool blood test
2. Complete a free colonoscopy
Aim 2. Evaluate program outcomes, including screening rates, cancers detected, and program
costs.
The primary outcome is screening completion.
Program setting. The John Peter Smith Hospital Health System (JPS) is a safety-net health
care system serving Tarrant County, Texas (including Fort Worth), with over 850,000 yearly
patient encounters. JPS qualifies as a safety-net health system based on a commitment to
deliver health care to uninsured, Medicaid participants, and other vulnerable patients18,
and is recognized as a disproportionate share hospital. JPS offers a tax-subsidized charity
medical program called JPS Connection for uninsured Tarrant County residents who are not
eligible for state or federal assistance programs such as Medicaid, with qualification based
on federal poverty income levels.
Target population. Our specific project target population includes men and women, aged 54 to
64, without prior CRC screening, of all races/ethnicities (including African Americans,
Hispanics, and Whites), who are primary English or Spanish language speaking, and uninsured
but enrolled in the JPS Connection medical assistance program. We include only those
individuals who qualify and are enrolled in the JPS Connection medical assistance program to
ensure that all included patients have access to a primary provider, as well as surgical and
medical cancer care, in the event that a patient has a cancer diagnosed.
TREATMENT (INTERVENTION) We will screen the administrative dataset that we are using to
identify potential study participants for individuals who meet inclusion criteria. All
patients selected to one of the programmatic screening approaches (Mailed FIT or Mailed
Colonoscopy invitation) will receive the same, structured approach for encouragement of
completion of CRC screening with the exception of the initial screening modality offered
(e.g. FIT or colonoscopy). In addition, patients selected for program intervention will also
be free to engage in usual medical care, and any associated visit-based screening at the
discretion and preference of the individual and primary medical provider.
Mailed invitation program procedures. Every 3 months, ¼ of the patient group selected for
the mail out program will receive an electronic, automated phone call, alerting them that an
invitation to participate in CRC screening will be mailed to them shortly. All invitees,
regardless of screen-group, will receive: 1) Invitation to participate in CRC screening with
a specific test, including discussion of importance of screening, 2) Return card that may
request to not participate in screening/be contacted in the future ("opt out" request). The
invitations will be sent every 3 months in batches, rather than all at once, to allocate
manpower resources for program follow up, and colonoscopy services as necessary for positive
tests or screening requests.
Alert and reminder phone calls. At time of initial mailing of the invitation, a "TeleVox©"
automated phone message, with a pre-recorded script (in both English and Spanish) will be
generated to alert participants that an invitation is "in-the-mail." Fourteen days after
initial mailing of the invitation, a "TeleVox©" automated reminder to respond to the
invitation for screening with a pre-recorded script (in both English and Spanish) will be
generated for all participants. Twenty-one to 36 days after initial invitation to testing, a
"live" reminder phone call will be initiated by the screening coordination team for all
individuals who have not responded to screening invitation. Up to 2 attempts will be made to
contact individuals via phone; reaching a voice mail, an adult household member, or the
target study participant will be considered a successful attempt. Reaching a disconnected,
busy line, or line that rings with no answer on two attempts will be considered unsuccessful
attempt. Continued intervention and follow up will not be based on whether or not phone call
attempts were successful—all patients included in the program will be assessed for the
outcome of screening participation.
Invitation letters. The invitation letters for screening with FIT or colonoscopy will
contain the following elements: 1) Statement that risk of getting colon cancer increases
with age and that screening can reduce the consequences, 2) Invitation to a specific
modality, (FIT or colonoscopy) with a succinct description of the test, 3) Number to call
with questions, 4) In the case of colonoscopy invitation, number to call to sign up, 5)
Signature from a physician at JPS.
FIT procedures. Individuals assigned to FIT will be provided with written instructions on
how to collect the stool samples for FIT testing. Kits will be mailed using return envelopes
with pre-paid postage to a JPS.
Colonoscopy procedures. The colonoscopy invitation will consist of an explanation of
colonoscopy, as well as a phone number to call to schedule a colonoscopy ("direct book") or
a pre-colonoscopy clinic visit. The decision to "direct book" for colonoscopy or to arrange
for a pre-colonoscopy clinic visit will be based on screening nurse phone interview using a
short screening form. If potential medical contraindications to colonoscopy are noted, a
pre-colonoscopy visit will be scheduled with a physician at JPS. Patients with uncontrolled
medical conditions will be referred to primary physicians for further management and to
consider CRC screening once the condition is under control. Reasons for not scheduling
colonoscopy will be documented. The patient will receive a date and time assignment for the
colonoscopy procedure, and instructions on bowel preparation for the procedure. The
preparation kit will be mailed to the patient's home. Reminder calls 5-7 days prior to the
procedure to confirm the date and time of the procedure, review bowel preparation
instructions, and answer any questions will occur. The day of the procedure, a history and
physical will be performed to re-assess for any contraindications for colonoscopy. Polyps
identified will be removed completely, with repeat colonoscopy and/or surgery if polyp
removal not successful. Any mass lesions and any areas of inflamed or irregular colon mucosa
will undergo biopsy. Endoscopy findings will be reviewed with each participant.
Test Follow Up. Individuals with positive FIT will be contacted to schedule a colonoscopy,
with the goal of test completion within 8-12 weeks of test positivity. If phone contact for
test scheduling cannot be established, a certified letter will be sent. Individuals with
findings of adenoma or cancer on colonoscopy will be scheduled for a follow up,
post-colonoscopy visit with the endoscopist who performed the procedure. Individuals with
normal FIT or colonoscopy screening tests will have a letter mailed to his or her home, as
well as the primary outpatient clinic identified by administrative data.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
| Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
| Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
| Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
| Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
| Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
| Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
| Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
| Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |